Shenzhen Famayi Pharmaceutical Technology

Shenzhen Famayi Pharmaceutical Technology is a biotechnology company specializing in the discovery and development of innovative small molecule drugs targeting protein-protein interactions (PPI). Founded in 2021, the company utilizes its proprietary F-PPI platform to address difficult-to-drug targets within the RAS signaling pathway and other oncogenic drivers. Famayi's pipeline is primarily focused on oncology and immunology, with lead programs targeting SHP2 and SOS1. The company aims to provide next-generation precision medicines for patients with solid tumors through structure-based drug design and fragment-based discovery. Famayi is headquartered in Shenzhen and is supported by leading venture capital investors.